Bioclinica bolsters pharmacovigilance services through Synowledge buy

By Dan Stanton

- Last updated on GMT

Related tags Pharmacology

Bioclinica bolsters pharmacovigilance services through Synowledge buy
Bioclinica has acquired pharmacovigilance and regulatory tech firm Synowledge.

Pharmacovigilance, regulatory affairs and IT services will be added to clinical service company Bioclinica’s pharma and biotech offerings through the acquisition of Miami, Florida-based Synowledge, announced today.

“Synowledge is a highly regarded provider that biopharmaceutical corporations trust to manage the critical process of monitoring and reporting adverse drug events,”​ Bioclinica CEO John Hubbard said in a statement today.

“Its capabilities complement our deep scientific expertise and technology-enabled services that support our customers in developing and bringing new drugs to market as safely and efficiently as possible.”

Synowledge employs over 500 staff in offices in North America, Europe, India, and Japan, and Sankesh Abbhi - the company’s founder – expressed his pleasure at joining Bioclinica.

“Our companies share a deep commitment to serving our customers and supporting their goals through highly specialized expertise and tailored solutions. Together, we offer customers a broader set of services and increased access to resources that support their overall drug development process.”

Abbhi will serve as senior vice president and head of global safety and regulatory solutions at the merged entity.

The news is the latest in a series of expansions at Bioclinica. In July the firm added patient recruitment and retention services through the acquisition of MediciGroup​, days after announcing it had opened offices in London and Munich​ to support its imaging services.

Related news

Show more

Related products

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Related suppliers

Follow us


View more